Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Findings Support Development of Micromet's EpCAM-specific Antibody
Therapeutics

BETHESDA, MD - January 13, 2009 -- Micromet, Inc. (Nasdaq: MITI), a
biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases
today announced the publication of an article in the peer-reviewed
journal Nature Cell Biology[1] revealing a novel signalling function
of the epithelial cell adhesion molecule, or EpCAM (CD326), which is
expressed with high frequency on many types of solid tumors. Micromet
is developing two antibody drug candidates that target EpCAM: MT110,
a T-cell engaging BiTE® antibody, and adecatumumab (MT201), a human
monoclonal antibody.

Principal investigator and senior author of the article was
Micromet's scientific collaborator Olivier Gires at the Grosshadern
Hospital of Munich University, Germany. The new data by Gires and
colleagues show that only cancer cells have an actively signalling
form of EpCAM, while normal cells have an inactive form of EpCAM.
When normal cells received the activated form of EpCAM, as is found
in tumor cells, and were then injected into mice, they behaved like
cancer cells in that they formed tumors.

"The findings of our latest publication may explain why certain
cancer patients with a high level of EpCAM expression on their tumor
cells have a reduced overall survival compared to patients with low
levels of EpCAM on their tumor cells. Since activated EpCAM is
expressed on the surface of cancer cells and their stem cells, it is
a very promising target for our antibody-based drug candidates,"
commented Micromet's Senior Vice President and Chief Scientific
Officer, Patrick Baeuerle.

-more-
Micromet is developing two antibodies binding to EpCAM. MT110, an
EpCAM-specific BiTE antibody, is being tested in a phase 1 clinical
trial for the treatment of patients with gastrointestinal or lung
cancer. In addition, Micromet is conducting a phase 1 clinical trial
with adecatumumab, a human monoclonal antibody binding to EpCAM,
investigating its use in combination with docetaxel for patients with
metastatic breast cancer. A phase 2 study of adecatumumab in
colorectal cancer patients with liver metastases is planned to be
initiated this year.

[1]Dorothea Maetzel, Sabine Denzel, Brigitte Mack, Martin Canis,
Philip Went, Michael Benk, Cuong Kieu, Peer Papior, Patrick A.
Baeuerle, Markus Munz & Olivier Gires. Nuclear signalling by
tumor-associated antigen EpCAM. Nature Cell Biology. Published
online: 11 January 2009; | doi:10.1038/ncb1824

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company
with offices in Bethesda, Maryland and Munich, Germany. The Company
is developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. The Company uses its
proprietary BiTE® antibody platform to create a new class of
antibodies that specifically activate T cells from the patient's own
immune system to eliminate cancer cells or other disease-related
cells. Four of the Company's antibodies are currently in clinical
trials, with the remainder of its product pipeline in preclinical
development. The Company's lead program is a BiTE antibody known as
blinatumomab, or MT103. It is in a phase 2 clinical trial for the
treatment of patients with acute lymphoblastic leukemia and a phase 1
clinical trial for the treatment of patients with non-Hodgkin's
lymphoma. Micromet is developing blinatumomab in collaboration with
MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE
antibody in clinical development is MT110, which targets the
epithelial cell adhesion molecule (EpCAM). The Company owns all
rights to MT 110, which is currently in a phase 1 clinical trial for
the treatment of patients with solid tumors. The Company's third
clinical stage antibody is adecatumumab, also known as MT201, a
conventional human monoclonal antibody that targets EpCAM-expressing
solid tumors. Micromet is developing adecatumumab in collaboration
with Merck Serono in

-more-

a phase 1b clinical trial evaluating adecatumumab in combination with
docetaxel for the treatment of patients with metastatic breast
cancer. Micromet has licensed a fourth clinical stage antibody,
MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a
phase 1 clinical trial for the treatment of patients with cancer. The
Company's preclinical programs include MT203, which is being
developed in collaboration with Nycomed. MT203 is a traditional human
antibody neutralizing the activity of granulocyte/macrophage colony
stimulating factor (GM-CSF), which has potential applications in the
treatment of inflammatory and autoimmune diseases, such as rheumatoid
arthritis, psoriasis, or multiple sclerosis. Additional BiTE
antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively,
are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be
materially different from historical results or from any future
results expressed or implied by such forward-looking statements.
These forward-looking statements include statements regarding the
relevance of EpCAM as a drug target, the efficacy and intended
utilization of our product candidates and the development of our BiTE
antibody technology. You are urged to consider statements that
include the words "could," "may," "appear," "promising," "potential,"
"planned", or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, and the risk that additional information relating to the
safety, efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or

-more-

clinical trial data. These factors and others are more fully
discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal
quarter ended September 30, 2008, filed with the SEC on November 6,
2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and, as such, speak only
as of the date made. Micromet, Inc. undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise.

# # #

Contact Information

US Media: European Media:
Andrea tenBroek/Chris Stamm Ludger Wess
(781)-684-0770 +49 (40) 8816 5964
micromet@schwartz-pr.com ludger@akampion.com

US Investors: European Investors:
Susan Noonan Ines-Regina Buth
(212) 966-3650 +49 (30) 2363 2768
susan@sanoonan.com ines@akampion.com

--- End of Message ---

Micromet Inc.
6707 Democracy Boulevard, Suite 505 Bethesda USA

WKN:
A0JMQD; ISIN: US59509C1053;
Listed: Xetra Stars in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.